Advanced progress of the relationship between PCSK9 monoclonal antibodies and hyperglycemic adverse events
Purpose of ReviewLong-term use of statins had been confirmed to cause an increase in hyperglycemic adverse events (HAEs), whose mechanism has been well understood. Proprotein convertase subtilisin/kexin type 9 (PCSK9) monoclonal antibodies (PCSK9-mAbs), a kind of new lipid-lowering drug, can effecti...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2023-06-01
|
| Series: | Frontiers in Cardiovascular Medicine |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fcvm.2023.1117143/full |
| _version_ | 1797795162318962688 |
|---|---|
| author | Ruixing Zhang Ruixing Zhang Ruixing Zhang Yongxiang Wang Yongxiang Wang Yu Peng Yu Peng Jing Zhao Jing Zhao Zheng Zhang Zheng Zhang |
| author_facet | Ruixing Zhang Ruixing Zhang Ruixing Zhang Yongxiang Wang Yongxiang Wang Yu Peng Yu Peng Jing Zhao Jing Zhao Zheng Zhang Zheng Zhang |
| author_sort | Ruixing Zhang |
| collection | DOAJ |
| description | Purpose of ReviewLong-term use of statins had been confirmed to cause an increase in hyperglycemic adverse events (HAEs), whose mechanism has been well understood. Proprotein convertase subtilisin/kexin type 9 (PCSK9) monoclonal antibodies (PCSK9-mAbs), a kind of new lipid-lowering drug, can effectively reduce plasma low-density lipoprotein cholesterol levels in patients with CHD and have been widely used. However, animal experiments, Mendelian randomization studies, clinical researches and Meta-analyses which focused on the relationship between PCSK9-mAbs and HAEs had reached different conclusions, which has attracted great attention from clinicians.Recent FindingsThe newest FOURIER-OLE randomized controlled trial followed PCSK9-mAbs users for over 8 years, whose results suggested that long-term use of PCSK9-mAbs did not increase the incidence of HAEs. Newest Meta-analyses also indicated that there was no relationship between PCSK9-mAbs and NOD. Meanwhile, genetic polymorphisms and variants related to PCSK9 might have effects on HAEs.ConclusionAccording to the results of current studies, there is no significant relationship between PCSK9-mAbs and HAEs. However, longer-term follow-up studies are still needed to confirm it. Although PCSK9 genetic polymorphisms and variants may affect the possible occurrence of HAEs, there is no need to perform relevant genetic testing before applying PCSK9-mAbs. |
| first_indexed | 2024-03-13T03:13:43Z |
| format | Article |
| id | doaj.art-2f410ff201684bfd9b43a02b8d2033bc |
| institution | Directory Open Access Journal |
| issn | 2297-055X |
| language | English |
| last_indexed | 2024-03-13T03:13:43Z |
| publishDate | 2023-06-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Cardiovascular Medicine |
| spelling | doaj.art-2f410ff201684bfd9b43a02b8d2033bc2023-06-26T05:38:42ZengFrontiers Media S.A.Frontiers in Cardiovascular Medicine2297-055X2023-06-011010.3389/fcvm.2023.11171431117143Advanced progress of the relationship between PCSK9 monoclonal antibodies and hyperglycemic adverse eventsRuixing Zhang0Ruixing Zhang1Ruixing Zhang2Yongxiang Wang3Yongxiang Wang4Yu Peng5Yu Peng6Jing Zhao7Jing Zhao8Zheng Zhang9Zheng Zhang10The First Clinical Medical College, Lanzhou University, Lanzhou, ChinaDepartment of Heart Center, The First Hospital of Lanzhou University, Lanzhou, ChinaKey Laboratory for Cardiovascular Diseases of Gansu Province, The First Hospital of Lanzhou University, Lanzhou, ChinaDepartment of Heart Center, The First Hospital of Lanzhou University, Lanzhou, ChinaKey Laboratory for Cardiovascular Diseases of Gansu Province, The First Hospital of Lanzhou University, Lanzhou, ChinaDepartment of Heart Center, The First Hospital of Lanzhou University, Lanzhou, ChinaKey Laboratory for Cardiovascular Diseases of Gansu Province, The First Hospital of Lanzhou University, Lanzhou, ChinaDepartment of Heart Center, The First Hospital of Lanzhou University, Lanzhou, ChinaKey Laboratory for Cardiovascular Diseases of Gansu Province, The First Hospital of Lanzhou University, Lanzhou, ChinaDepartment of Heart Center, The First Hospital of Lanzhou University, Lanzhou, ChinaKey Laboratory for Cardiovascular Diseases of Gansu Province, The First Hospital of Lanzhou University, Lanzhou, ChinaPurpose of ReviewLong-term use of statins had been confirmed to cause an increase in hyperglycemic adverse events (HAEs), whose mechanism has been well understood. Proprotein convertase subtilisin/kexin type 9 (PCSK9) monoclonal antibodies (PCSK9-mAbs), a kind of new lipid-lowering drug, can effectively reduce plasma low-density lipoprotein cholesterol levels in patients with CHD and have been widely used. However, animal experiments, Mendelian randomization studies, clinical researches and Meta-analyses which focused on the relationship between PCSK9-mAbs and HAEs had reached different conclusions, which has attracted great attention from clinicians.Recent FindingsThe newest FOURIER-OLE randomized controlled trial followed PCSK9-mAbs users for over 8 years, whose results suggested that long-term use of PCSK9-mAbs did not increase the incidence of HAEs. Newest Meta-analyses also indicated that there was no relationship between PCSK9-mAbs and NOD. Meanwhile, genetic polymorphisms and variants related to PCSK9 might have effects on HAEs.ConclusionAccording to the results of current studies, there is no significant relationship between PCSK9-mAbs and HAEs. However, longer-term follow-up studies are still needed to confirm it. Although PCSK9 genetic polymorphisms and variants may affect the possible occurrence of HAEs, there is no need to perform relevant genetic testing before applying PCSK9-mAbs.https://www.frontiersin.org/articles/10.3389/fcvm.2023.1117143/fullproprotein convertase subtilisin/kexin type 9 monoclonal antibodieslipid metabolismhyperglycemic adverse eventscoronary heart diseasetype 2 diabetes mellitus |
| spellingShingle | Ruixing Zhang Ruixing Zhang Ruixing Zhang Yongxiang Wang Yongxiang Wang Yu Peng Yu Peng Jing Zhao Jing Zhao Zheng Zhang Zheng Zhang Advanced progress of the relationship between PCSK9 monoclonal antibodies and hyperglycemic adverse events Frontiers in Cardiovascular Medicine proprotein convertase subtilisin/kexin type 9 monoclonal antibodies lipid metabolism hyperglycemic adverse events coronary heart disease type 2 diabetes mellitus |
| title | Advanced progress of the relationship between PCSK9 monoclonal antibodies and hyperglycemic adverse events |
| title_full | Advanced progress of the relationship between PCSK9 monoclonal antibodies and hyperglycemic adverse events |
| title_fullStr | Advanced progress of the relationship between PCSK9 monoclonal antibodies and hyperglycemic adverse events |
| title_full_unstemmed | Advanced progress of the relationship between PCSK9 monoclonal antibodies and hyperglycemic adverse events |
| title_short | Advanced progress of the relationship between PCSK9 monoclonal antibodies and hyperglycemic adverse events |
| title_sort | advanced progress of the relationship between pcsk9 monoclonal antibodies and hyperglycemic adverse events |
| topic | proprotein convertase subtilisin/kexin type 9 monoclonal antibodies lipid metabolism hyperglycemic adverse events coronary heart disease type 2 diabetes mellitus |
| url | https://www.frontiersin.org/articles/10.3389/fcvm.2023.1117143/full |
| work_keys_str_mv | AT ruixingzhang advancedprogressoftherelationshipbetweenpcsk9monoclonalantibodiesandhyperglycemicadverseevents AT ruixingzhang advancedprogressoftherelationshipbetweenpcsk9monoclonalantibodiesandhyperglycemicadverseevents AT ruixingzhang advancedprogressoftherelationshipbetweenpcsk9monoclonalantibodiesandhyperglycemicadverseevents AT yongxiangwang advancedprogressoftherelationshipbetweenpcsk9monoclonalantibodiesandhyperglycemicadverseevents AT yongxiangwang advancedprogressoftherelationshipbetweenpcsk9monoclonalantibodiesandhyperglycemicadverseevents AT yupeng advancedprogressoftherelationshipbetweenpcsk9monoclonalantibodiesandhyperglycemicadverseevents AT yupeng advancedprogressoftherelationshipbetweenpcsk9monoclonalantibodiesandhyperglycemicadverseevents AT jingzhao advancedprogressoftherelationshipbetweenpcsk9monoclonalantibodiesandhyperglycemicadverseevents AT jingzhao advancedprogressoftherelationshipbetweenpcsk9monoclonalantibodiesandhyperglycemicadverseevents AT zhengzhang advancedprogressoftherelationshipbetweenpcsk9monoclonalantibodiesandhyperglycemicadverseevents AT zhengzhang advancedprogressoftherelationshipbetweenpcsk9monoclonalantibodiesandhyperglycemicadverseevents |